Shannon R McCurdy, MD
Assistant Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Department: Medicine
Contact information
Perelman Center for Advanced Medicine
3400 Civic Center Blvd
12 South Pavilion
Philadelphia, PA 19104
3400 Civic Center Blvd
12 South Pavilion
Philadelphia, PA 19104
Office: 12156140698
Fax: 2156155890
Fax: 2156155890
Publications
Education:
BA (English and Pre-Medical )
Emory University , 2005.
MD (Medicine)
Georgetown University School of Medicine, 2009.
Permanent linkBA (English and Pre-Medical )
Emory University , 2005.
MD (Medicine)
Georgetown University School of Medicine, 2009.
Description of Clinical Expertise
While HLA-matched related sibling donors are available for ~30%, they are more difficult to identify for older patients given that their siblings will also be older and often have medical comorbidities that exclude them from donating. In addition, older donor age may be associated with a greater risk of graft failure. As such, I have worked to expand the availability of allogeneic transplantation to older patients through HLA-haploidentical transplantation with post-transplant cyclophosphamide, which allows us to use children, grandchildren, nieces, and nephews as donors. Another former barrier to transplanting older patients was the intensity of conditioning. Historically allogeneic transplantation was limited to patients younger than 50 due to high treatment-related mortality associated with myeloablation. In my work, I demonstrated that utilizing nonmyeloablative HLA-haploidentical transplantation for patients in their 70’s and 60’s yielded similar outcomes to patients undergoing transplantation in their 50’s. In addition to an expertise in allogeneic transplantation, I specialize in the treatment of all phases of care for patients with acute lymphoblastic leukemia and myeloid diseases including acute myeloid leukemia, myelodysplastic syndrome, myeloproliferative neoplasms, and chronic myeloid leukemia.Description of Research Expertise
Allogeneic blood or marrow transplantation is the only potentially curative option for patients with relapsed, refractory, or high-risk hematologic malignancies. Unfortunately, only a third of patients have an available HLA-matched related donor. Partially HLA-mismatched related (HLA-haploidentical) transplantation allows identification of a donor for the vast majority of patients. In the past, HLA-haploidentical transplantation was associated with excessive nonrelapse mortality and poor overall survival. My research has contributed to the understanding of a novel technique that utilizes post-transplant cyclophosphamide as graft-versus-host disease prophylaxis after HLA-haploidentical transplantation. Using risk stratification with the disease risk index developed by Armand et al., I demonstrated that outcomes after nonmyeloablative HLA-haploidentical transplantation are comparable to that after reduced intensity HLA-matched transplantation. Similar to my work in older patients described above, I have also shown that nonmyeloablative HLA-haploidentical transplantation is safe and effective for pediatric and young adult patients. In addition, I have contributed to research examining early biomarkers, such as ST2, as predictors of nonrelapse mortality after HLA-haploidentical transplantation. Finally, to improve outcomes further, I have conducted research to examine the association of donor characteristics with transplantation outcomes. I showed that parent donors were associated with more graft failure when compared with sibling or offspring donors, but that survival was no different. Importantly, in that analysis, survival was affected by recipient age with recipients over 55 having inferior survival to younger patients. This work supports my proposed research agenda to evaluate the utility of the frailty phenotype tools to predict an older patient’s risk of nonrelapse mortality after induction chemotherapy and allogeneic transplantation as discussed in this proposal. Finally, my research has contributed to the widespread adoption of HLA-haploidentical transplantation with post-transplant cyclophosphamide, I have advanced the understanding of how we can improve its outcomes further, and I hope to continue to advance the field through studying frailty phenotype assessments in older patients with leukemia and myeloid malignancies undergoing induction then consolidative allogeneic transplantation.Selected Publications
Pashna Munshi and Shannon R. McCurdy: Age Barriers in Allogeneic Hematopoietic Cell Transplantation: Raising the Silver Curtain. American Journal of Hematology 2024.Anand S Bhagwat, MD, PhD, Leonel Torres*, Olga Shestova, PhD*, Maksim Shestov*, Noelle V. Frey, MD, MS, Elizabeth O Hexner, MD, MSTR, Selina M Luger, MD, FRCPC, Alison W Loren, MD, Mary Ellen Martin, MD, Shannon R McCurdy, MD, Alexander Perl, Edward A. Stadtmauer, MD, James K. Mangan, MD, Jennifer Brogdon, PhD, Joseph A Fraietta, PhD*, Wei-Ting Hwang, PhD*, Don L. Siegel, MD, PhD, Saad S. Kenderian, MD, David L. Porter, MD, Carl June, MD and Saar Gill, MD, PhD: Cytokine Release Syndrome Results in Reduced AML Killing By CD123 CAR T Cells. Oral Abstract at the American Society of Hematology Annual Meeting Dec 2023.
Matthew P Connor, MD1, Neeharika Prathapa, MBBS1*, Noelle V. Frey, MD, MS1, Saar Gill, MD, PhD1, Elizabeth O Hexner, MD, MSTR1, Ximena Jordan Bruno, MD1, Catherine Lai, MD1, Alison W Loren, MD1, Selina M Luger, MD, FRCPC1, Andrew H Matthews, MD1*, Shannon R McCurdy, MD1, Alexander Perl1, David L. Porter, MD1, Arlene Zeringue2*, Joseph H. Oved, MD3,4, Timothy S Olson, MD, PhD4,5, Keith W Pratz, MD1 and Daria V Babushok, MD, PhD1,4: Hypomethylating Agents Are Associated with High Rates of Hematologic Toxicity in Patients with Secondary MDS/AML That Develops after Acquired Aplastic Anemia. American Society of Hematology, Annual Meeting Dec 2023.
Ashley D Hadjis, MD*, Griffin W White*, Christopher Catania*, Noelle V. Frey, MD, MS, Saar Gill, MD, PhD, Elizabeth O Hexner, MD, MSTR, Ximena Jordan Bruno, MD, Catherine Lai, MD, Andrew H Matthews, MD*, Mary Ellen Martin, MD, Daria V Babushok, MD, PhD, Alexander Perl, David L. Porter, MD, Alison W Loren, MD, Keith W Pratz, MD, Selina M Luger, MD, FRCPC and Shannon R McCurdy, MD: Frail and Pre-Frail Older Adults with Acute Myeloid Leukemia Have Inferior Survival Due to Higher Rates of Disease-Related Deaths. Oral Abstract at the American Society of Hematology Annual Meeting Dec 2023.
Margaret Rowe, MD1*, Daria V Babushok, MD, PhD2, Martin Carroll, MD3, Alison Carulli, PharmD1*, Noelle V. Frey, MD, MS4, Saar Gill, MD, PhD4, Elizabeth O Hexner, MD, MSTR4, Rebecca Hirsh, MD1*, Nasheed Hossain, MD5*, Catherine Lai, MD4, Alison W Loren, MD4, Selina M Luger, MD, FRCPC6, Ivan Maillard4, Shannon R McCurdy, MD4, Andrew H Matthews, MD4*, Mary Ellen Martin, MD4, Vikram R Paralkar, MD4, Alexander Perl4, David L. Porter, MD7, Keith W Pratz, MD4,5, Edward A. Stadtmauer, MD8 and Ximena Jordan Bruno, MD4: Comparing Cairo Bishop and Howard Criteria for Identifying Clinically Meaningful Tumor Lysis Syndrome Among Acute Myeloid Leukemia Patients Treated with Venetoclax and Hypomethylating Agents: A Single Center Experience. American Society of Hematology Annual Meeting Dec 2023.
Seiichi Villalona, MD, MA1*, Xin Wang, MD2, Peter Gabriel, MD3*, Abigail Doucette4*, Shannon R McCurdy, MD2, Alexander Perl2, Selina M Luger, MD, FRCPC2, Noelle V. Frey, MD, MS2, Ximena Jordan Bruno, MD2, Elizabeth O Hexner, MD, MSTR2, Daria V Babushok, MD, PhD5, David L. Porter, MD2, Alison W Loren, MD2, Keith W Pratz, MD2 and Catherine Lai, MD: Patient-Reported Outcome Measures Associated with Overall Survival and Acute Care Use in Patients with Newly Diagnosed Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Acute Lymphoblastic Leukemia. American Society of Hematology Annual Meeting Dec 2023.
Xin Wang, MD1, Phyllis Gimotty, PhD2*, Andrew H Matthews, MD1*, Ronac Mamtani, MD, MSCE1*, Selina M Luger, MD, FRCPC1, Elizabeth O Hexner, MD, MSTR1, Daria V Babushok, MD, PhD1, Shannon R McCurdy, MD1, Noelle V. Frey, MD, MS1, Ximena Jordan Bruno, MD1, David L. Porter, MD1, Saar Gill, MD, PhD1, Mary Ellen Martin, MD1, Vikram R Paralkar, MD1, Ivan Maillard1, Alison W Loren, MD1, Alexander Perl1, Keith W Pratz, MD1, Kelly D. Getz, PhD, MPH2,3* and Catherine Lai, MD1: Evolving Racial/Ethnic Disparities in AML Survival in the Novel Therapy Era: Real-World Evidence of Improved Survival in Older Patients with the Largest Improvement in Non-Hispanic Black Patients. Oral Abstract at the American Society of Hematology Annual Meetings Dec 2023.
Andrew Artz, MD, MS, Brent R. Logan, PhD*, Wael Saber, MD, MS, Nancy Geller, PhD*, Anna Bellach, Ph.D.*, Jianqun Kou, MS*, William Wood, MD, MPH, John M. McCarty, MD, Thomas G. Knight, MD, Lyndsey Runaas*, Laura Johnston, Jeremy Walston*, Ryotaro Nakamura, MD, Tammy Schuler*, Asmita Mishra, MD, MBA, Joseph Uberti, MD, PhD, Parastoo B. Dahi, MD*, Jennifer N. Saultz, DO, Shannon R. McCurdy, MD, Lawrence Morris, MD, Philip Imus, MD, William J. Hogan, MD, Kalyan Nadiminti, MBBS, Vijaya Raj Bhatt, MD, Deborah Mattila, BA*, Bailey Protz*, Steven M. Devine, MD, Mary M. Horowitz, MD and Mohamed Sorror, MD, MSc: The Composite Health Risk Assessment Model (CHARM) to Predict 1-year Non-relapse Mortality (NRM) among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704. Oral Abstract American Society of Hematology Annual Meeting, #109. Dec 2023.
Ashley D. Hadjis and Shannon R. McCurdy: Post-Transplantation Cyclophosphamide: Changing the Paradigm of HLA-Mismatching. American Society of Histocompatibility and Immunogenetics 47(3): 13-20, Sept 2023.
Jain T, Tsai HL, Elmariah H, Vachhani P, Karantanos T, Wall S, Gondek L, Bashey A, Keyzner A, Tamari R, Grunwald M, Abedin S, Nadiminti K, Iqbal M, Gerds A, Viswabandya A, McCurdy S, Malki MA, Varadhan R, Ali H, Gupta V, Jones RJ, Otoukesh S.: Haploidentical Donor Blood or Marrow Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms: Results from a North American Collaboration. Haematologica July 2023.